Edition:
United States

Critical Outcome Technologies Inc (COT.V)

COT.V on TSX Venture Exchange

0.46CAD
--
Change (% chg)

-- (--)
Prev Close
$0.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
126,017
52-wk High
$0.90
52-wk Low
$0.36

Latest Key Developments (Source: Significant Developments)

Critical Outcome Technologies Q4 loss per share c$0.018
Wednesday, 3 Aug 2016 07:30am EDT 

Critical Outcome Technologies :Q4 loss per share c$0.018.  Full Article

Critical Outcome Tech appoints Alison Silva as new president
Wednesday, 15 Jun 2016 09:15am EDT 

Critical Outcome Technologies Inc : Appointment of alison silva as new president of company effective july 5, 2016 .Critical outcome technologies appoints experienced industry executive as new president.  Full Article

Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study
Monday, 6 Jun 2016 08:30am EDT 

Critical Outcome Technologies Inc :Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study.  Full Article

Critical Outcome Technologies Inc completes private placement
Tuesday, 4 Aug 2015 05:00pm EDT 

Critical Outcome Technologies Inc:Completed the final tranche of its previously announced non-brokered private placement with the issuance of 2,788,533 units (the "Units") at a price of $0.30 per Unit for gross Canadian dollar proceeds of about $837,000.Raised gross Canadian proceeds from the offering of approximately $1,287,000 through the sale of 4,288,533 Units.  Full Article

FDA grants IND to Critical Outcome Technologies for COTI-2
Tuesday, 26 May 2015 08:30am EDT 

Critical Outcome Technologies Inc:Says that the U.S. Food and Drug Administration granted investigational new drug status for COTI-2, the Company's small molecule activator of misfolded mutant p53 protein, in gynecological cancers.  Full Article

Critical Outcome Technologies Inc adds first European patent to growing intellectual property protection for COTI-2
Monday, 11 May 2015 08:30am EDT 

Critical Outcome Technologies Inc:Says European Patent Office has granted company european patent no. 2121681 for its lead cancer drug candidate, COTI-2.This patent covers composition of matter of COTI-2, the Company's small molecule activator of misfolded mutant p53 protein.Issuance of this European patent provides company with additional protection and licensing opportunities for COTI-2 franchise in European markets.European Patent No. 2121681 covers number of chemical structures in the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, methods of manufacturing compounds and use of the compounds in treatment of cancer in European market until Jan. 2028.  Full Article

Critical Outcome Technologies Inc files investigational new drug application with FDA for COTI-2
Monday, 27 Apr 2015 08:33am EDT 

Critical Outcome Technologies Inc:Filing of an Investigational New Drug (IND) application with U.S. Food and Drug Administration's Center for Drug Evaluation and Research (FDA).For COTI-2, potential breakthrough therapy intended for the treatment of women with gynecological cancers with p53 mutations.Advanced gynecological cancers have a particularly high prevalence rate (as high as 95%) of p53 mutations.Says IND application is a complete description of the chemistry, non-clinical pharmacodynamics and pharmacokinetics, safety toxicology, manufacturing and other relevant information related to COTI-2 as a potential treatment for patients with p53 mutations.Subject to FDA granting IND application, company intends to initiate Phase 1 clinical trial of an oral formulation of COTI-2 in patients with gynecological cancers (cervical, endometrial and ovarian) at University of Texas MD Anderson Cancer Center in Houston.Extensive preclinical studies have demonstrated COTI-2's ability to restore mutant p53 function and thus induce cancer cell death in cancers with many common p53 mutations.In upcoming clinical trial, company intends to determine primarily safety of COTI-2, as well as obtain some indications of efficacy.  Full Article

Critical Outcome Technologies receives First U.S. Patent for Next Generation HIV Treatment
Wednesday, 15 Apr 2015 08:30am EDT 

Critical Outcome Technologies Inc:Has been granted a U.S. patent for the Company's novel HIV integrase inhibitor compounds.United States Patent No. 8987272 covers novel compounds useful in the treatment of HIV and methods of treating HIV using the compounds.The patent provides coverage for these compounds and methods until the year 2031. Equivalent patents are pending in Canada and Europe.  Full Article

More From Around the Web

BRIEF-Critical outcome technologies announces departure of chief scientific officer

* Critical outcome technologies announces departure of chief scientific officer Source text for Eikon: Further company coverage: